{
    "medicine_id": "d2da38956b27797b7d10e52aaf4fda600bdca4cb",
    "platform_id": "DB15699",
    "metadata": {
        "name": "Tecartus 2000000 1 68mL Suspension",
        "composition": "2000000 1 68mL Brexucabtagene autoleucel",
        "clinical_particulars": {
            "therapeutic_indications": "Brexucabtagene autoleucel is a modified autologous chimeric antigen receptor CAR T cell immunotherapy indicated for the treatment of relapsed or refractory mantle cell lymphoma MCL in adult patients L15148 Brexucabtagene autoleucel has been granted accelerated approval based on results from a single arm open label multicentre clinical trial continued approval may be contingent on confirmatory trials L15148",
            "contraindications": {
                "disease": "Toxicity information regarding brexucabtagene autoleucel is not readily available Patients experiencing an overdose are at an increased risk of severe adverse effects such as severe infections severe and prolonged cytopenia hypogammaglobulinemia cytokine release syndrome and neurological toxicities A216188 L15148 Symptomatic and supportive measures are recommended",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Brexucabtagene autoleucel is an autologous T cell immunotherapy employing a CD19 directed chimeric antigen receptor CAR to direct modified T cells to bind to and subsequently destroy cancerous B cells L15148 Like other CAR T cell therapies brexucabtagene autoleucel has a durable response in the single arm ZUMA 2 trial the median time to peak CAR T cell levels was 15 days and 60 of assayed patients had detectable levels of CAR T cells at 24 months following the single infusion A216148 As brexucabtagene autoleucel recognizes both normal and cancerous B cells adverse effects related to B cell depletion are expected including severe and prolonged cytopenia severe infections neurological effects hypogammaglobulinemia and the potential to develop secondary malignancies Patients should be advised not to drive or operate heavy machinery for eight weeks following infusion Hypersensitivity reactions may occur during infusion L15148",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brexucabtagene autoleucel"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brexucabtagene autoleucel"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Brexucabtagene autoleucel"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Brexucabtagene autoleucel"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}